Ox-01 neuroprotective candidate selected for evaluation in new US NINDS programme
FreeOx Biotech FreeOx Biotech has announced that its uric acid-based leading compound, Ox-01, has been officially selected by the US National Institute of Neurological Disorders and Stroke (NINDS) to be evaluated on its new stroke-dedicated StrokeNet Thrombectomy...
FreeOx’s Ox-01 to be Evaluated as Adjunct Mechanical Thrombectomy Therapy for Stroke in NINDS-Funded Phase 2/3 Clinical Trial on Stroke-dedicated STEP Platform
FreeOx Biotech FreeOx's Ox-01 Outperforms 3 Candidates from Big Pharma; Phase 2/3 Expected to Initiate in 2025 BARCELONA / PALO ALTO, Spain, Nov. 15, 2024 /PRNewswire-PRWeb/ -- FreeOx Biotech, a clinical stage biopharmaceutical company pioneering the development of a...
FreeOx Biotech Formally Launches Seed Round to Fund Phase III Pivotal Trial
FreeOx Biotech Adds Leadership for Advancing Ox-01 to Phase III and Commercialization
FreeOx Biotech lead asset recommended by nih/ninds span network for further development
FreeOx Biotech Adds Leadership for Advancing Ox-01 to Phase III and Commercialization
A preclinical trial by the U.S. National Institutes of Health validates the efficacy of Uric Acid for ischaemic stroke
Uric Acid was shown to improve the prognosis of ischaemic stroke in a preclinical study carried out on rodents within the framework of the Stroke Preclinical Assessment Network (SPAN) in the USA, a network of experimental laboratories focusing on cerebral ischaemia,...
A study conducted at Hospital Clínic Barcelona and led by Dr Ángel Chamorro, Co-Founder and Scientific Director of FreeOx Biotech, changes the paradigm in ischaemic stroke treatment
Researchers at Hospital Clínic Barcelona and the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) have shown that administration of a fibrinolytic drug after performing embolectomy in ischaemic stroke patients increases the possibilities of recovering...
FreeOx acquires the patent for the drug Ox-01 in the US for ischaemic stroke
FreeOx Biotech has been granted a patent for its most advanced drug, Ox-01, by the United States Patent and Trademark Office (USPTO). The patent protects the use of Ox-01 until 2038 for patients with ischaemic stroke treated with mechanical thrombectomy. “This grant...
Dr. Ángel Chamorro: “La meitat dels pacients que pateixen un ictus tornen a fer vida normal”
En motiu del Dia Mundial de l'Ictus, el programa La nit dels ignorants de Catalunya Ràdio ha entrevistat el Dr. Ángel Chamorro, un dels principals especialistes en l'ictus, director de la Unitat Funcional de Patologia Vascular Cerebral de l'Hospital Clínic de...
Dr. Ángel Chamorro: “Estamos disminuyendo las consecuencias del ictus, pero los nuevos casos crecen”
Entrevista del Dr. Ángel Chamorro en Misderechos.club en la cual explica los síntomas, factores de riesgo e incidencia del ictus, una patología que afecta a 17 millones de personas en todo el mundo. El Dr. Chamorro es neurólogo, director de la Unidad Funcional de...
FreeOx and AEC Partners sign agreement to bring new stroke drugs to market
FreeOx Biotech has taken on AEC Partners as a strategic partner in the company to accelerate development and marketing of its drug to treat brain ischemia. The priority drug is Ox-01, which is about to begin phase-III clinical trials. AEC Partners analysed the brand...
